Drug discovery is one of AI's most transformative real-world applications — and unlike many AI claims, the results here are concrete and verified.
**AlphaFold (DeepMind, 2020–2024):**
Protein folding — predicting a protein's 3D structure from its amino acid sequence — was biology's grand challenge. It took years of experiments per protein. AlphaFold 2 solved it with deep learning, predicting structures with near-experimental accuracy in hours. DeepMind made AlphaFold open source and released predictions for 200+ million proteins — essentially the entire known protein universe. This is the largest scientific database ever created.
**What it unlocks:**
Every drug target is a protein. Understanding a protein's shape tells you how to design a molecule to bind to it. AlphaFold compresses what was years of structural biology into hours, at zero marginal cost.
**Current AI drug discovery pipeline:**
1. **Target identification**: AI finds which proteins are implicated in a disease using genomics data
2. **Structure prediction**: AlphaFold (or RosettaFold) predicts 3D shape
3. **Molecule design**: Generative AI designs candidate drug molecules (Insilico Medicine, Recursion, AbSci)
4. **ADMET prediction**: AI predicts absorption, distribution, metabolism, excretion, toxicity
5. **Clinical trial optimization**: AI finds optimal patient populations and trial designs
**Real results so far:**
- Insilico Medicine's AI-designed drug entered Phase 2 clinical trials — going from AI design to trials in under 4 years (industry average: 10-15 years)
- Isomorphic Labs (DeepMind spinout) partnered with Eli Lilly and Novartis for multi-billion dollar AI drug discovery deals
**Key takeaway:** AlphaFold solved protein structure prediction, unlocking AI-accelerated drug discovery. The first fully AI-designed drugs are already in human trials.